Adjuvant immunotherapy (BCG) in stage D prostate cancer

P. D. Guinan, T. John, G. Baumgartner, B. Sundar, R. J. Ablin

Research output: Contribution to journalArticlepeer-review

21 Scopus citations


Thirty-three patients with advanced prostate cancer were prospectively randomized to receive either Bacillus Calmette-Guerin (BCG) adjuvant immunotherapy plus conventional therapy or conventional therapy alone. Conventional therapy consisted of estrogens or observation. There was a statistically significantly (p<0.05) longer survival in the 16 BCG-treated patients (42 weeks) than in the 17 control patients (29 weeks).

Original languageEnglish (US)
Pages (from-to)65-68
Number of pages4
JournalUnknown Journal
Issue number1
StatePublished - 1982
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Adjuvant immunotherapy (BCG) in stage D prostate cancer'. Together they form a unique fingerprint.

Cite this